Tenvie Therapeutics

Tenvie Therapeutics is a private, preclinical-stage biotech with a specialized focus on central nervous system (CNS) drug development. The company leverages a validated, CNS-centric small molecule engine to create precisely engineered compounds that are either highly brain-penetrant or peripherally restricted, offering clinical development optionality. Its pipeline, initially acquired from Denali Therapeutics, targets NLRP3 inflammasome and other pathways, with early data showing promise in reversing hypothalamic inflammation and driving weight loss in obesity models. Led by a seasoned team of CNS drug developers, Tenvie is positioned to address high-need areas in neurology and metabolic diseases.

A CNS-centric small molecule product engine that precisely engineers compounds to be either highly CNS-penetrant or peripherally restricted, targeting inflammation, metabolic dysfunction, and lysosomal function.

Tenvie competes in the crowded NLRP3 inflammasome inhibitor space, with several biopharma companies developing candidates for inflammatory and metabolic diseases. Its key differentiation is the deliberate engineering of CNS-penetrant vs. peripheral compounds, a strategy aimed at unlocking neurological indications and minimizing side effects for systemic use.